drugset
drugset / Trial / NCT01774747

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

NCT01774747 ↗

Phase 1 Terminated 47 enrolled Sumitomo Pharma America, Inc.
RandomizedSingle-groupQuadruple-blindTreatment

Summary

Double-blind, placebo-controlled, multiple ascending oral dose evaluation of the safety, tolerability, and pharmacokinetics of DSP 1053 and its metabolites in healthy subjects and in subjects with major depressive disorder

Timeline

Start
2012-12
Primary completion
2014-04
Completion
2014-04

Outcome

Outcome not reported

Stopped (Business): “This program was terminated for financial reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject DSP-1053 Unknown 10 mg Oral
Subject DSP-1053 Unknown 15 mg Oral
Subject DSP-1053 Unknown 20 mg Oral
Subject DSP-1053 Unknown 30 mg Oral
Subject DSP-1053 Unknown 45 mg Oral
Subject DSP-1053 Unknown 60 mg Oral
Subject DSP-1053 Unknown 90 mg Oral

Indications

No indication recorded.